Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (207)	6/4/1998 1:17:00 PM
From: Anthony Wong	Read Replies (2) \| Respond to of 1722

Now, if you pay $295 monthly, you can get all the Viagra news: June 04, 1998 12:09 PM PR NEWSWIRE PUBLISHER TO LAUNCH VIAGRA NEWSLETTER KING OF PRUSSIA, Pa., June 4 /PRNewswire/ -- The initial positive news surrounding the impotency drug Viagra has started to give way to negative reports. Articles publicizing six deaths of men who were taking the drug and heart medication have hit the press, but Viagra maker Pfizer (NYSE: PFE) says it believes the information available in the cases "does not suggest any risk to patients which is not already described in the product label or known for the population being treated with Viagra." In international news, health officials in Vietnam have banned Viagra pending a Ministry of Health review, and reports of deaths have come out of Brazil and Egypt. On the positive side of the news, Pfizer has announced that the advisory committee of the European Medicines Evaluation Agency has adopted a positive opinion of Viagra. A California man has sued Aetna over its refusal to cover Viagra prescription costs. The U.S. government is considering a Medicaid reimbursement directive to states. The wife of one man is suing him for $2 million, claiming Viagra led him to infidelity. On the business front, retail heavyweights Wal-Mart and Kmart are engaged in a Viagra price war. To follow the myriad developments regarding Viagra, Mealey Publications this month will begin publishing Mealey's Viagra Watch, a newsletter on the controversy and claims surrounding this new drug. Instead of devoting countless hours seeking information on the medication from a variety of sources, subscribers will be able to find all the latest developments in one place. Any litigation surrounding the impotency drug will be covered with the same precision and detail thousands of subscribers have come to expect from Mealey Publications. The monthly newsletter is just $295. To subscribe, contact Mealey's Customer Service Department at 800-MEALEYS (632-5397) or 610-768-7800 or by e-mail at news@mealeys.com. Mealey's is recognized as the leader in litigation reporting. Subjects covered in other litigation reports include: asbestos; breast implants; fen-phen / Redux and diet drugs; the Year 2000 (Y2K) problem; latex; drugs and medical devices; toxic torts; lead paint exposure; Superfund; intellectual property; expert admissibility (Daubert); reinsurance; insurance insolvency; insurance fraud; insurance coverage litigation in the environmental and emerging areas; insurance bad faith; intellectual property; biotechnology; patents; international arbitration and tobacco. CONTACT: Scott Jacobs of Mealey Publications, 610-768-6800 11:53 EDT 9542 06/04/98 11:53 EDT HT